指南与共识呼吸衰竭与机械通气重症综合管理与镇静镇痛

推进急性呼吸窘迫综合征的精准医学

Advancing precision medicine for acute respiratory distress syndrome.
PubMed 文献 · Lancet Respir Med · 2021-07-23
一句话结论ARDS具有临床与生物学异质性,精准医学策略通过匹配治疗与最可能获益的亚组来改善疗效,需在临床试验中评估治疗效应异质性。

急性呼吸窘迫综合征(ARDS)是一种异质性临床综合征,尽管对肺损伤病理生理的理解不断深入,目前仅针对通气相关肺损伤的治疗被一致证明有益,ARDS发病率和死亡率仍高。许多临床前有希望的候选治疗在人体试验中无效,部分原因可能是临床和生物学异质性改变了治疗反应性。2019年10月美国国家心肺血液研究所召开多学科专家研讨会,探讨加速ARDS精准医学的研究机会与挑战,包括精准医学方法的理由与挑战、临床前模型的作用、队列研究的关键特征以及支持精准医学策略开发和验证的新型临床试验方法。本文总结研讨会讨论、建议和未解决的问题;尽管研讨会早于COVID-19大流行,但大流行凸显了ARDS精准治疗的迫切需求。

要点

  • ARDS是异质性临床综合征,目前仅针对通气相关肺损伤的治疗被一致证明有益,但发病率和死亡率仍高。
  • 许多临床前有希望的候选治疗在人体试验中无效,可能至少部分源于临床和生物学异质性改变了治疗反应性。
  • 精准医学方法通过匹配治疗与预期最可能获益的亚组来更好地考虑异质性,亚组初步可部分通过评估临床试验中的治疗效应异质性来识别。
  • 2019年10月美国国家心肺血液研究所召开多学科专家研讨会,探讨加速ARDS精准医学的研究机会与挑战。
  • 研讨会讨论了精准医学方法的理由与挑战、临床前ARDS模型的作用、推进精准医学的队列研究关键特征以及支持精准医学策略开发和验证的新型临床试验方法。

适用人群与场景

  • 急性呼吸窘迫综合征(ARDS)患者。

研究设计与关键结果

  • 2019年10月美国国家心肺血液研究所召集多学科专家研讨会,探讨加速ARDS精准医学的研究机会与挑战。
  • 研讨会讨论主题包括精准医学方法在ARDS中的理由与挑战、临床前ARDS模型在精准医学中的作用、推进精准医学的队列研究关键特征以及支持精准医学策略开发和验证的新型临床试验方法。
  • 本文总结研讨会讨论、建议和未解决的问题;研讨会早于COVID-19大流行,但大流行凸显了ARDS精准治疗的迫切需求。

证据类型、等级与局限

  • 证据类型:位置论文(Position Paper),总结多学科专家研讨会讨论、建议和未解决的问题。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Acute respiratory distress syndrome (ARDS) is a heterogeneous clinical syndrome. Understanding of the complex pathways involved in lung injury pathogenesis, resolution, and repair has grown considerably in recent decades. Nevertheless, to date, only therapies targeting ventilation-induced lung injury have consistently proven beneficial, and despite these gains, ARDS morbidity and mortality remain high. Many candidate therapies with promise in preclinical studies have been ineffective in human trials, probably at least in part due to clinical and biological heterogeneity that modifies treatment responsiveness in human ARDS. A precision medicine approach to ARDS seeks to better account for this heterogeneity by matching therapies to subgroups of patients that are anticipated to be most likely to benefit, which initially might be identified in part by assessing for heterogeneity of treatment effect in clinical trials. In October 2019, the US National Heart, Lung, and Blood Institute convened a workshop of multidisciplinary experts to explore research opportunities and challenges for accelerating precision medicine in ARDS. Topics of discussion included the rationale and challenges for a precision medicine approach in ARDS, the roles of preclinical ARDS models in precision medicine, essential features of cohort studies to advance precision medicine, and novel approaches to clinical trials to support development and validation of a precision medicine strategy. In this Position Paper, we summarise workshop discussions, recommendations, and unresolved questions for advancing precision medicine in ARDS. Although the workshop took place before the COVID-19 pandemic began, the pandemic has highlighted the urgent need for precision therapies for ARDS as the global scientific community grapples with many of the key concepts, innovations, and challenges discussed at this workshop.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Beitler JR, Thompson BT, Baron RM, et al. Advancing precision medicine for acute respiratory distress syndrome. Lancet Respir Med. 2021. PMID: 34310901. doi:10.1016/S2213-2600(21)00157-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。